Early Detection Test, Biomarkers and Targets for Drug Resistant Cancer

[Guest guest]

Power3 Secures Exclusive Rights from UT M. D. Cancer Center for

Early Detection Test, Biomarkers and Targets for Drug Resistant Cancer

Tuesday August 9, 9:00 am ET

THE WOODLANDS, Texas, Aug. 9 /PRNewswire-FirstCall/ -- Power3 Medical

Products, Inc. (OTC: PWRM.PK - News) a leading proteomics company, today

announced that it has obtained the exclusive worldwide license to patents

and technologies for early detection screening tests, identified protein

biomarkers and drug targets for cancer patients' resistance to drug therapy.

The technology was developed through joint collaboration between the

scientific team of Power3 Medical and The University of Texas M. D.

Cancer Center.

According to Dr. Ira L. Goldknopf, Chief Scientific Officer and Head of the

Scientific Team at Power3, " By utilizing our very sensitive and reproducible

proteomic methods with definitive patient samples, we discovered a series of

proteins whose concentrations in the bone marrow aspirate samples, taken

from Chronic Myelogenous Leukemia (CML) patients before treatment,

demonstrated a consistent correlation with whether the patients subsequently

responded to the treatment with a particular drug. The identities of these

proteins, which apparently detect the presence of drug resistant cancer

cells prior to treatment, also indicate a potential to design drugs to kill

both sensitive and resistant cancer cells. "

" By the time drug resistance is detected in CML by current technology it is

usually too late to save the patient. This technology holds the promise of

detecting cancer resistance to drugs before treatment begins and offers the

possibility of designing drugs to increase their effectiveness to defeat

resistant cancer and to thereby prevent recurrence of the disease, " comments

B. Rash, Chairman and CEO of Power3 Medical.